Generics North America (NAFTA) Industry Guide 2014-2023

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the NAFTA generics market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

Key Highlights

– The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $116,377.6 million in 2018.The Mexico was the fastest growing country, with a CAGR of 12.5% over the 2014-18 period.

– Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $104,841.0 million in 2018. This was followed by Mexico and Canada, with a value of $6,337.2 and $5,199.4 million, respectively.

– The US is expected to lead the generics industry in the NAFTA bloc, with a value of $124,641.3 million in 2023, followed by Mexico and Canada with expected values of $8,519.8 and $6,002.7 million, respectively.

Scope

– Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market

– Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market

– Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance

– Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume

– Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to buy

- What was the size of the NAFTA generics market by value in 2018?

- What will be the size of the NAFTA generics market in 2023?

- What factors are affecting the strength of competition in the NAFTA generics market?

- How has the market performed over the last five years?

- How large is the NAFTA generics market in relation to its regional counterparts?

Table of Contents

Table of Contents

1 Introduction

1.1. What is this report about?

1.2. Who is the target reader?

1.3. How to use this report

1.4. Definitions

2 NAFTA Generics

2.1. Industry Outlook

3 Generics in Canada

3.1. Market Overview

3.2. Market Data

3.3. Market Segmentation

3.4. Market outlook

3.5. Five forces analysis

3.6. Macroeconomic Indicators

3.7. Country data

4 Generics in Mexico

4.1. Market Overview

4.2. Market Data

4.3. Market Segmentation

4.4. Market outlook

4.5. Five forces analysis

4.6. Macroeconomic Indicators

4.7. Country data

5 Generics in the United States

5.1. Market Overview

5.2. Market Data

5.3. Market Segmentation

5.4. Market outlook

5.5. Five forces analysis

5.6. Macroeconomic Indicators

5.7. Country data

6 Company Profiles

6.1. Pfizer Inc.

6.2. Teva Pharmaceutical Industries Limited

6.3. Apotex, Inc.

6.4. Mylan N.V.

Appendix

List of Tables

List of Tables

Table 1: NAFTA countries Generics industry, revenue ($m), 2014-23

Table 2: NAFTA countries Generics industry, revenue ($m), 2014-18

Table 3: NAFTA countries Generics industry forecast, revenue ($m), 2018-23

Table 4: Canada generics market value: $ million, 2014-18

Table 5: Canada generics market volume: % of total pharma, 2014-18

Table 6: Canada generics market geography segmentation: $ million, 2018

Table 7: Canada generics market value forecast: $ million, 2018-23

Table 8: Canada generics market volume forecast: % of total pharma, 2018-23

Table 9: Canada size of population (million), 2014-18

Table 10: Canada gdp (constant 2005 prices, $ billion), 2014-18

Table 11: Canada gdp (current prices, $ billion), 2014-18

Table 12: Canada inflation, 2014-18

Table 13: Canada consumer price index (absolute), 2014-18

Table 14: Canada exchange rate, 2014-18

Table 15: Mexico generics market value: $ million, 2014-18

Table 16: Mexico generics market volume: % of total pharma, 2014-18

Table 17: Mexico generics market geography segmentation: $ million, 2018

Table 18: Mexico generics market value forecast: $ million, 2018-23

Table 19: Mexico generics market volume forecast: % of total pharma, 2018-23

Table 20: Mexico size of population (million), 2014-18

Table 21: Mexico gdp (constant 2005 prices, $ billion), 2014-18

Table 22: Mexico gdp (current prices, $ billion), 2014-18

Table 23: Mexico inflation, 2014-18

Table 24: Mexico consumer price index (absolute), 2014-18

Table 25: Mexico exchange rate, 2014-18

Table 26: United States generics market value: $ million, 2014-18

Table 27: United States generics market volume: % of total pharma, 2014-18

Table 28: United States generics market geography segmentation: $ million, 2018

Table 29: United States generics market value forecast: $ million, 2018-23

Table 30: United States generics market volume forecast: % of total pharma, 2018-23

Table 31: United States size of population (million), 2014-18

Table 32: United States gdp (constant 2005 prices, $ billion), 2014-18

Table 33: United States gdp (current prices, $ billion), 2014-18

Table 34: United States inflation, 2014-18

Table 35: United States consumer price index (absolute), 2014-18

Table 36: United States exchange rate, 2014-18

Table 37: Pfizer Inc.: key facts

Table 38: Pfizer Inc.: Annual Financial Ratios

Table 39: Pfizer Inc.: Key Employees

Table 40: Pfizer Inc.: Key Employees Continued

Table 41: Teva Pharmaceutical Industries Limited: key facts

Table 42: Teva Pharmaceutical Industries Limited: Annual Financial Ratios

Table 43: Teva Pharmaceutical Industries Limited: Key Employees

Table 44: Apotex, Inc.: key facts

Table 45: Apotex, Inc.: Key Employees

Table 46: Mylan N.V.: key facts

Table 47: Mylan N.V.: Annual Financial Ratios

Table 48: Mylan N.V.: Key Employees

List of Figures

List of Figures

Figure 1: NAFTA countries Generics industry, revenue ($m), 2014-23

Figure 2: NAFTA countries Generics industry, revenue ($m), 2014-18

Figure 3: NAFTA countries Generics industry forecast, revenue ($m), 2018-23

Figure 4: Canada generics market value: $ million, 2014-18

Figure 5: Canada generics market volume: % of total pharma, 2014-18

Figure 6: Canada generics market geography segmentation: % share, by value, 2018

Figure 7: Canada generics market value forecast: $ million, 2018-23

Figure 8: Canada generics market volume forecast: % of total pharma, 2018-23

Figure 9: Forces driving competition in the generics market in Canada, 2018

Figure 10: Drivers of buyer power in the generics market in Canada, 2018

Figure 11: Drivers of supplier power in the generics market in Canada, 2018

Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2018

Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2018

Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2018

Figure 15: Mexico generics market value: $ million, 2014-18

Figure 16: Mexico generics market volume: % of total pharma, 2014-18

Figure 17: Mexico generics market geography segmentation: % share, by value, 2018

Figure 18: Mexico generics market value forecast: $ million, 2018-23

Figure 19: Mexico generics market volume forecast: % of total pharma, 2018-23

Figure 20: Forces driving competition in the generics market in Mexico, 2018

Figure 21: Drivers of buyer power in the generics market in Mexico, 2018

Figure 22: Drivers of supplier power in the generics market in Mexico, 2018

Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2018

Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2018

Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2018

Figure 26: United States generics market value: $ million, 2014-18

Figure 27: United States generics market volume: % of total pharma, 2014-18

Figure 28: United States generics market geography segmentation: % share, by value, 2018

Figure 29: United States generics market value forecast: $ million, 2018-23

Figure 30: United States generics market volume forecast: % of total pharma, 2018-23

Figure 31: Forces driving competition in the generics market in the United States, 2018

Figure 32: Drivers of buyer power in the generics market in the United States, 2018

Figure 33: Drivers of supplier power in the generics market in the United States, 2018

Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2018

Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2018

Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2018

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports